Title:

Early SARS-CoV-2 reinfections within 60 days highlight the need to consider antigenic variations together with duration of immunity in defining retesting policies

Authors:

Louis Nevejan¹, Lize Cuypers¹, Lies Laenen¹, Liselotte Van Loo², François Vermeulen², Elke Wollants³, Ignace Van Hecke¹, Stefanie Desmet¹,³, Katrien Lagrou¹,³, Piet Maes³, Emmanuel André¹,³

Affiliations:

¹ Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens, UZ Leuven – University Hospitals Leuven, Leuven, Belgium

² Department of Pediatrics, UZ Leuven – University Hospitals Leuven, Leuven, Belgium

³ KU Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Epidemiological Virology, Leuven, Belgium

⁴ KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Microbiology, Leuven, Belgium

Corresponding author:

Louis Nevejan

Department of Laboratory Medicine, National Reference Center for Respiratory Pathogens

UZ Leuven – University Hospitals Leuven

Herastraat 49

3000 Leuven – BELGIUM

louis.nevejan@uzleuven.be

Conflicts of interest: LN, LC, LL, LVL, FV, EW, IVH, SD, KL, PM, EA: none to declare

Funding source: none to declare

Acknowledgment: UZ Leuven, as national reference center for respiratory pathogens, is supported by Sciensano, which is gratefully acknowledged

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract:

The emergence of the SARS-CoV-2 Omicron variant, characterized by a significant antigenic diversity compared to the previous Delta variant, had led to a decrease in antibody efficacy in both convalescent and vaccinees’ sera resulting in high number of reinfections and breakthrough cases worldwide. However, to date, reinfections are defined by the ECDC as two positive tests ≥60 days apart, influencing retesting policies after an initial positive test in several European countries. We illustrate by a clinical case supplemental by epidemiological data that early reinfections do occur within 60 days especially in young, unvaccinated individuals. In older patient groups, unvaccinated and patients with a basic vaccination scheme are more vulnerable to reinfections compared to patients who received a first booster vaccine. For this reason, we consider that the duration of protection offered by a previous infection should be reconsidered, in particular when a shift between consecutive SARS-CoV-2 variants occurs.

Text:

The sequential emergence of SARS-CoV-2 variants of concern (VOCs), characterized by both an antigenic drift and higher transmissibility, has been observed in all countries around the world at least three times during the last 13 months (1). These abrupt viral population replacements inevitably impact the residual population immunity, independently from the timing of a previous infection. While the SARS-CoV-2 Delta variant showed a limited antigenic diversity with previous VOCs, Omicron differs more significantly from other VOCs than any previous variant did at the time they emerged (2). The resulting decrease of antibody efficacy in both convalescent and vaccinees’ sera drives the high number of reinfection and breakthrough cases observed with Omicron compared to the observations made during the previous waves (3–6).

To date, reinfections with SARS-CoV-2 are defined by the European Centre for Disease Prevention and Control (ECDC) as two positive tests ≥60 days apart (technical report April 8, 2021) (7). This definition has influenced testing strategies in several countries, and many countries therefore do not recommend retesting patients for six months after a positive test. We consider that this definition needs to be revised.

To illustrate our point, we report here a case of an immunocompetent boy with no significant medical history, who was infected with SARS-CoV-2 Delta variant (≥7.0 log copies/mL, sublineage AY.43) in early December, 2021, concomitant with an outbreak at the patient’s school (Table 1). The patient’s sibling and one parent were infected as well (≥7.0 log copies/mL respectively ≥5.0 - <7.0 log copies/mL). All three developed mild COVID-19 symptoms. The other parent, boosted 1 month before, tested negative twice. Due to an unrelated trauma two weeks later, the patient was admitted...
to the hospital for surgery. Systematic SARS-CoV-2 screening performed at admission detected a low viral load (<3.0 log copies/mL), interpreted as viral remnant of the past infection 16 days earlier and typing of this sample was not possible due to low viral load. Three weeks later, the patient was readmitted for a second stage surgery. Preprocedural SARS-CoV-2 screening detected a strong positive result (5.1 log copies/mL) with Omicron BA.1 variant, therefore only 39 days after the patient’s infection with Delta. The patient remained pauci-symptomatic. High-risk contact screening of the patient’s brother detected a low viral load (<3.0 log copies/mL, untypable due to the low viral load), the mother tested SARS-CoV-2 negative and the father was not retested.

Further, to put this clinical case into a wider epidemiological context, we estimated the incidence of early reinfections with 1) Omicron BA.1 after Delta infection and 2) with Omicron BA.2 after BA.1 infections in a community setting (Flemish Brabant, Belgium).

Between December 1, 2021 and February 7, 2022 (n = 9 weeks), a period characterized by the viral replacement of Delta by Omicron BA.1, a total of 56,831 ambulatory patients tested SARS-CoV-2 positive at the federal testing platform located in Leuven, Belgium. Among these, 0.16% (91 out of 56,831) had the S-gene detected in a first sample using the TaqPath PCR test (suggestive of Delta infection), while S-gene target failure (SGTF) was reported in a second positive sample within this time period (cycle threshold N gene <27.8), assuming a reinfection with Omicron BA.1 briefly after Delta infection.

Similarly, between January 1, 2022 and March 10, 2022 (n = 9 weeks), a period characterized by viral replacement of Omicron BA.1 by BA.2, a total of 48,829 patients tested SARS-CoV-2 positive. Among these, 0.01% (5 out of 48,829) presented an SGTF in a first sample but had an S-gene detected in a second positive sample. Considering the epidemiological context during the latter period in this region, reinfections with Omicron BA.2 after BA.1 infection were suspected in these patients.

In Figure 1, we report the age and vaccination status of these 96 patients with documented early reinfection, compared to the vaccination rate for the same age groups in the same geographic region (Flanders, Belgium) (8). Early reinfections were most frequently observed among young unvaccinated patients (<12 years old). In all age groups, patients with early reinfection had a lower vaccination rate compared to the corresponding age groups in the general population. Boosted patients had the lowest risk of early SARS-CoV-2 reinfection. Median time between the last vaccine dose and reinfection in all patients was 172 days (IQR 76-195 days). Median time between the two positive samples with different VOC was 47 days (range 17-65 days).

Previous large retrospective cohort studies showing a prolonged maintenance of protection against reinfection should be questioned in the context of Omicron (3). Our data confirms that early Omicron
BA.1 reinfection (<60 days) after Delta infection and BA.2 reinfection after a BA.1 infection can occur, especially in young, unvaccinated individuals. In older patient groups, unvaccinated and patients with a basic vaccination scheme are more vulnerable to reinfections compared to patients who received a first booster vaccine. Data from Denmark (9) suggests reinfection usually results in mild disease not requiring hospitalization as is illustrated by this reported case.

For this reason, we consider that the duration of protection offered by a previous infection should be reconsidered, in particular when a shift between consecutive SARS-CoV-2 variants occurs. Testing policies should not assume that patients do not need to be retested within a period of 60 days, as reinfections, especially in unvaccinated young patients, are not inconceivable within this timeframe. It has been repeatedly observed that a full viral population replacement can occur in a matter of a few weeks, and such phenomenon will continue to impact the duration and efficacy of immunity in the future.
Table 1. Results of SARS-CoV-2 screening and vaccination status in the patient and his family. All samples were analyzed using reverse transcription polymerase chain reaction, whole genome sequencing was performed on SARS-CoV-2 positive samples in the Belgian National Reference Center for Respiratory Pathogens (10).

<table>
<thead>
<tr>
<th></th>
<th>PATIENT</th>
<th>SIBLING</th>
<th>PARENT</th>
<th>PARENT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-vaccinated</td>
<td>08/2021 BNT162b2</td>
<td>06/2021 BNT162b2</td>
<td>02/2021 ChAdOx1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>09/2021 BNT162b2</td>
<td>07/2021 BNT162b2</td>
<td>05/2021 ChAdOx1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11/2021 BNT162b2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIRST INFECTION</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DECEMBER 2021</td>
<td>early</td>
<td>SARS-CoV-2 very strong positive</td>
<td>SARS-CoV-2 very strong positive</td>
<td>SARS-CoV-2 strong positive</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥7.0 log copies/mL</td>
<td>≥7.0 log copies/mL</td>
<td>≥5 - &lt;7.0 log copies/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Delta (AY.43)</td>
<td>Delta (AY.43)</td>
<td>Delta (AY.43)</td>
</tr>
<tr>
<td></td>
<td>early</td>
<td>SARS-CoV-2 weak positive</td>
<td>SARS-CoV-2 negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&lt;3.0 log copies/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>mid</td>
<td>SARS-CoV-2 5.05 log copies/mL</td>
<td>SARS-CoV-2 negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Omicron (BA.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SECOND INFECTION</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JANUARY 2022</td>
<td>early</td>
<td>SARS-CoV-2 negative</td>
<td>SARS-CoV-2 weak positive</td>
<td>SARS-CoV-2 negative</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt;3.0 log copies/mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>mid</td>
<td>SARS-CoV-2 negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>untypable</td>
<td></td>
</tr>
</tbody>
</table>

All rights reserved. No reuse allowed without permission.
Figure 1. Number of patients with documented SARS-CoV-2 reinfection including vaccination status compared with age corresponding vaccination coverage in the community (i.e. Flanders, Belgium)

Number of patients with documented SARS-CoV-2 reinfection including vaccination status compared with age corresponding vaccination coverage in the community

- Unvaccinated
- 1/2 basic vaccination
- Basic vaccination
- Boosted

Age (years) | Number of patients with reinfections / vaccination coverage in community
---|---
4-11 (community) | 59
5-11 (community) | 4 (41%)
12-17 (community) | 3 (34%)
12-17 (community) | 1 (11%)
18-44 (community) | 5 (53%)
18-44 (community) | 13 (15%)
45-64 (community) | 3 (41%)
45-64 (community) | 4 (15%)

All rights reserved. No reuse allowed without permission.
References


2. Van der Straeten K, Guerra D, Van Gils MJ, Bontjer I, Caniels TG, Van Willigen HDG, et al. Mapping the antigenic diversification of SARS-CoV-2. medRxiv [Internet]. 2022; Available from: https://www.medrxiv.org/content/10.1101/2022.01.03.21268582v1%0Ahttps://www.medrxiv.org/content/10.1101/2022.01.03.21268582v1.abstract


significance of Omicron BA.1 infection followed by Corresponding author. medRxiv [Internet]. 2022; Available from: https://doi.org/10.1101/2022.02.19.22271112